Dopamine melanin-loaded PC12 cells: A model for studies on pigmented neurons

Pigment Cell Research

Volumn 18, Issue 4, 2005, Pages 306-314

  Östergren, Anna ^a   Svensson, Anne Lie ^a   Lindquist, Nils Gunnar ^a   Brittebo, Eva B ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Amyloid beta; Caspase 3; Dopamine melanin; Glucose regulating protein 78; Neuromelanin; PC12 cells

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CASPASE 3; DOPAMINE; GLUCOSE REGULATED PROTEIN 78; MELANIN; NEUROMELANIN;

ANIMAL CELL; ARTICLE; CELL STRAIN; CELL STRUCTURE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; PHEOCHROMOCYTOMA CELL; PROTEIN TRANSPORT; RAT; WESTERN BLOTTING;

AMYLOID BETA-PROTEIN; ANIMALS; CASPASE 3; CASPASES; CELL SURVIVAL; ENZYME ACTIVATION; HEAT-SHOCK PROTEINS; MELANINS; MICROSCOPY, ELECTRON, TRANSMISSION; MOLECULAR CHAPERONES; NEURONS; PC12 CELLS; PEPTIDE FRAGMENTS; PIGMENTATION; RATS;

ANIMALIA;

EID: 22744455019     PISSN: 08935785     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0749.2005.00239.x     Document Type: Article

References (51)

1. Barden, H., and Levine, S. (1983). Histochemical observations on rodent brain melanin. Brain Res. Bull. 10, 847-851.
2. Ben-Shachar, D., Riederer, P., and Youdim, M.B. (1991). Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57, 1609-1614.
3. Binns, F., Chapman, R.F., Robson, N.C., Swan, G.A., and Waggott, A. (1970). Studies related to the chemistry of melanins. 8. The pyrrolecarboxylic acids formed by oxidation or hydrolysis of melanins derived from 3,4-dihydroxyphenethylamine or (plus or minus)-3,4-dihydroxyphenylalanine. J. Chem. Soc. [Perkin 1] 8, 1128-1134.
4. Cotzias, G.G., Papavasiliou, P.S., and Miller, S.T. (1964). Manganese in melanin. Nature 201, 1228-1229.
5. D'Ischia, M., and Prota, G. (1997). Biosynthesis, structure, and function of neuromelanin and its relation to Parkinson's disease: a critical update. Pigment Cell Res. 10, 370-376.
6. Das, K.L., Abramson, M.B., and Katzman, R. (1978). Neuronal pigments: spectroscopic characterisation of human brain melanin. J. Neurochem. 30, 601-605.
7. Double, K.L., Riederer, P., and Gerlach, M. (1999). The significance of neuromelanin in Parkinson's disease. Drug News Dev. 12, 333-340.
8. Enochs, W.S., Nilges, M.J., and Swartz, H.M. (1993). Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy. J. Neurochem. 61, 68-79.
9. Forno, L.S. (1966). Pathology of parkinsonism. A preliminary report of 24 cases. J. Neurosurg. 23, 266-271.
10. Greene, L.A., and Tischler, A.S. (1982). PC12 pheochromocytoma cultures in neurobiological research. Adv. Cell. Neurobiol. 3, 373-414.
11. Greenfield, J.G., and Bosanquet, F.D. (1953). The brain-stem lesions in parkinsonism. J. Neurol. Neurosurg. Psychiatry 16, 213-226.
12. Herrero, M.T., Hirsch, E.G., Kastner, A., Ruberg, M., Luquin, M.R., Laguna, J., Javoy-Agid, F., Obeso, J.A., and Agid, Y. (1993). Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? Neuroscience 56, 499-511.
13. Hirsch, E., Graybiel, A.M., and Agid, Y.A. (1988). Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348.
14. Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., and Izzo, A.A. (2004). Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J. Neurochem. 89, 134-141.
15. Jang, J.H., and Surh, Y.J. (2003). Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic. Biol. Med. 34, 1100-1110.
16. Jones, D.C., Prabhakaran, K., Li, L., Gunasekar, P.G., Shou, Y., Borowitz, J.L., and Isom, G.E. (2003). Cyanide enhancement of dopamine-induced apoptosis in mesencephalic cells involves mitochondrial dysfunction and oxidative stress. Neurotoxicology 24, 333-342.
17. Juurlink, B.H. (1988). Lysosomal accumulation of neuromelanin-like material in astrocytes after exposure to norepinephrine. J. Neuropathol. Exp. Neurol. 47, 48-53.
18. Kadota, T., Yamaai, T., Saitoh, Y., Kawashima, S., Moroi, K., and Kadota, K. (1995). Expression of a dopamine transporter in PC12h cells: an immunohistochemical study with an antipeptide antibody. J. Histochem. Cytochem. 44, 989-996.
19. Kaufman, R.J. (1999). Molecular chaperones and the heat shock response. Sponsored by Cold Spring Harbor Laboratory, 6-10 May 1998. Biochim. Biophys. Acta 1423, R13-R27.
20. Korytowski, W., Sarna, T., and Zar ba, M. (1995). Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation. Arch. Biochem. Biophys. 319, 142-148.
21. Lindquist, N.G. (1973). Accumulation of drugs on melanin. Acta Radiol. Diagn. (Stockh.) 325, 1-92.
22. Lindquist, N.G., Larsson, B.S., and Lyden-Sokolowski, A. (1987). Neuromelanin and its possible protective and destructive properties. Pigment Cell Res. 1, 133-136.
23. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
24. Lyden, A., Bondesson, U., Larsson, B.S., and Lindquist, N.G. (1983). Melanin affinity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, an inducer of chronic parkinsonism in humans. Acta Pharmacol. Toxicol. (Copenh.) 53, 429-432.
25. Lyden, A., Larsson, B.S., and Lindquist, N.G. (1984). Melanin affinity of manganese. Acta Pharmacol. Toxicol. (Copenh.) 55, 133-138.
26. Marsden, C.D. (1961). Pigmentation in the nucleus substantiae nigrae of mammals. J. Anat. 95, 256-261.
27. Offen, D., Ziv, I., Barzilai, A., Gorodin, S., Glater, E., Hochman, A., and Melamed, E. (1997). Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease. Neurochem. Int. 31, 207-216.
28. Offen, D., Gorodin, S., Melamed, E., Hanania, J., and Malik, Z. (1999). Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease. Neurosci. Lett. 260, 101-104.
29. Ostergren, A., Annas, A., Skog, K., Lindquist, N.G., and Brittebo, E.B. (2004). Long-term retention of neurotoxic beta-carbolines in brain neuromelanin. J. Neural Transm. 111, 141-157.
30. Pike, C.J., Burdick, D., Walencewicz, A.J., Glabe, C.G., and Cotman, C.W. (1993). Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676-1687.
31. Pilas, B., Sarna, T., Kalyanaraman, B., and Swartz, H.M. (1988). The effect of melanin on iron associated decomposition of hydrogen peroxide. Free Radic. Biol. Med. 4, 285-293.
32. Prota, G. (1992). Neuromelanin. In Melanins and Melanogenesis, G. Prota, ed. (San Diego, CA: Academic Press), pp. 119-133.
33. Rabacchi, S.A., Friedman, W.J., Shelanski, M.L., and Troy, C.M. (2004). Divergence of the apoptotic pathways induced by 4-hydroxynonenal and amyloid beta-protein. Neurobiol. Aging 25, 1057-1066.
34. Stepien, K., Zajdel, A., Wilczok, A., Wilczok, T., Grzelak, A., Mateja, A., Soszynski, M., and Bartosz, G. (2000). Dopamine-melanin protects against tyrosine nitration, tryptophan oxidation and Ca(2+)-ATPase inactivation induced by peroxynitrite. Biochim. Biophys. Acta 1523, 189-195.
35. Sulzer, D., Bogulavsky, J., Larsen, K.E. et al. (2000). Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. USA 97, 11869-11874.
36. Usunoff, K.G., Itzev, D.E., Ovtscharoff, W.A., and Marani, E. (2002). Neuromelanin in the human brain: a review and atlas of pigmented cells in the substantia nigra. Arch. Physiol. Biochem. 110, 257-369.
37. Wakamatsu, K., Fujikawa, K., Zucca, F.A., Zecca, L., and Ito, S. (2003). The structure of neuromelanin as studied by chemical degradative methods. J. Neurochem. 86, 1015-1023.
38. Weingarten, P., and Zhou, Q.Y. (2001). Protection of intracellular dopamine cytotoxicity by dopamine disposition and metabolism factors. J. Neurochem. 77, 776-785.
39. Weldon, D.T., Rogers, S.D., Ghilardi, J.R., Finke, M.P., Cleary, J.P., O'Hare, E., Esler, W.P., Maggio, J.E., and Mantyh, P.W. (1998). Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J. Neurosci. 18, 2161-2173.
40. Wilczok, T., Stepien, K., Dzierzega-Lecznar, A., Zajdel, A., and Wilczok, A. (1999). Model neuromelanins as antioxidative agents during lipid peroxidation. Neurotox. Res. 1, 141-147.
41. Wolf, B.B., Schuler, M., Echeverri, F., and Green, D.R. (1999). Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation. J. Biol. Chem. 274, 30651-30656.
42. Yamin, R., Malgeri, E.G., Sloane, J.A., McGraw, W.T., and Abraham, C.R. (1999). Metalloendopeptidase EC 3.4.24.15 is necessary for Alzheimer's amyloid-beta peptide degradation. J. Biol. Chem. 274, 18777-18784.
43. Youdim, M.B., Ben-Shachar, D., and Riederer, P. (1994). The enigma of neuromelanin in Parkinson's disease substantia nigra. J. Neural Transm. Suppl. 43, 113-122.
44. Young, P., Barza, M., Kane, A., and Baum, J. (1979). Radioactive and bioassay of intraocular antibiotics: double-assay technique to compare penicillin G, cefamandole, and gentamicin in ocular tissues in vivo. Arch. Ophthalmol. 97, 717-720.
45. Zecca, L., Mecacci, C., Seraglia, R., and Parati, E. (1992). The chemical characterization of melanin contained in substantia nigra of human brain. Biochim. Biophys. Acta 1138, 6-10.
46. Zecca, L., Pietra, R., Goj, C., Mecacci, C., Radice, D., and Sabbioni, E. (1994). Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J. Neurochem. 62, 1097-1101.
47. Zecca, L., Tampellini, D., Gerlach, M., Riederer, P., Fariello, R.G., and Sulzer, D. (2001). Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol. Pathol. 54, 414-418.
48. Zecca, L., Fariello, R., Riederer, P., Sulzer, D., Gatti, A., and Tampellini, D. (2002a). The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett. 510, 216-220.
49. Zecca, L., Tampellini, D., Gatti, A., Crippa, R., Eisner, M., Sulzer, D., Ito, S., Fariello, R., and Gallorini, M. (2002b). The neuromelanin of human substantia nigra and its interaction with metals. J. Neural Transm. 109, 663-672.
50. Zhou, Y., and Richardson, J.S. (1996). Cholesterol protects PC12 cells from beta-amyloid induced calcium disordering and cytotoxicity. Neuroreport 7, 2487-2490.
51. Zucca, F.A., Giaveri, G., Gallorini, M. et al. (2004). The neuromelanin of human substantia nigra: physiological and pathogenic aspects. Pigment Cell Res. 17, 610-617.